Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie …
AbbVie
Deal likely to close this month. This is an election merger with proration. Be careful with PCYC options. There are cash mergers. There are stock mergers. There are mergers that are a mix of cash and stock. Some mergers …
Moving Parts
Investors in Pharmacyclics, Inc. (NASD: PCYC) saw new options become available this week, for the December 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PCYC options …
AbbVie has entered into a $21 billion agreement to acquire Pharmacyclics, gaining access to its potential blockbuster cancer treatment Imbruvica AbbVie Inc (NYSE:ABBV) announced yesterday that it has entered …
The stock repurchase authorization permits shares to be repurchased ...
AbbVie
The deal -- the latest example of a big drugmaker swooping on a biotech firm to refill its medicine pipeline -- confounds expectations that Pharmacyclics would sell out to Johnson & Johnson (JNJ.N). AbbVie will pay …
Reuters
Pharmacyclics Inc. (NASDAQ: PCYC) has seen its stock surge in the past week as rumors swirl about a potential acquisition. News finally broke late Wednesday that there was an official buyout in the works by …
NASDAQ
Investors in Pharmacyclics, Inc. (Symbol: PCYC) saw new options become available this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PCYC options …
Transaction TermsAbbVie will acquire all of the outstanding shares of common stock of Pharmacyclics through a tender offer, followed by a second-step merger. In the tender offer, AbbVie will offer to acquire all of the …
Acquire